Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
299 0 |
Căutarea după subiecte similare conform CZU |
616.155.194-036.1-085 (1) |
Patologia sistemului circulator, a vaselor sanguine. Tulburări cardiovasculare (975) |
SM ISO690:2012 SGHIBNEVA-BOBEICO, Nina. Evaluation of the effectiveness of interferon alpha treatment in patients with primary myelofibrosis. In: Revista de Ştiinţe ale Sănătăţii din Moldova, 2022, nr. 3 An.1(29), p. 175. ISSN 2345-1467. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Revista de Ştiinţe ale Sănătăţii din Moldova | ||||||
Numărul 3 An.1(29) / 2022 / ISSN 2345-1467 | ||||||
|
||||||
CZU: 616.155.194-036.1-085 | ||||||
Pag. 175-175 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Primary myelofibrosis (PM) is a myeloproliferative neoplasm of unknown etiology. Insufficient data on the evolution of young patients due to lack of studies and long-term evidence of this disease are of interest to the investigator. Objective of the study. Evaluation of the efficacy of interferon alfa treatment in patients with PM. Material and methods. A retrospective clinical-analytic study was performed using data from the Institute of Oncology. In the Republic of Moldova are 450 patients with MP and now 16 patients have been treated with interferon-alpha therapy for 2 years. Results. In 33.3% of cases, the improvement of the general condition and the normalization of the complete blood count was obtained. Four (33.3%) patients discontinued treatment for various reasons. In 33.3% of cases, the normalization of the blood count occurred after increasing the dose of interferon to 12-15 MIU per week. In 16.7% of patients, interferon therapy was just started and there was a tendency to decrease the number of platelets and leukocytes. One patient receives interferon enhanced by hydroxycarbamide. In 8.3% of cases, there was a stabilization of the tumor process over 2 years. Conclusions. The analysis shows that interferon may be used as an alternative therapy to chemotherapy, particularly in young patients and those who do not tolerate other antineoplastic agents. |
||||||
Cuvinte-cheie primary myelofibrosis, treatment, interferon, observation, mielofibroză primară, Tratament, interferon, evidența |
||||||
|